US biopharma Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase III TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback